@article{45fa74ac1e7146a3a3d208629bf93142,
title = "Hodgkin Lymphoma, Version 2.2022 Featured Updates to the NCCN Guidelines",
abstract = "Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.",
author = "Hoppe, {Richard T.} and Advani, {Ranjana H.} and Ai, {Weiyun Z.} and Ambinder, {Richard F.} and Philippe Armand and Bello, {Celeste M.} and Benitez, {Cecil M.} and Weina Chen and Bouthaina Dabaja and Daly, {Megan E.} and Gordon, {Leo I.} and Neil Hansen and Herrera, {Alex F.} and Hochberg, {Ephraim P.} and Johnston, {Patrick B.} and Kaminski, {Mark S.} and Kelsey, {Christopher R.} and Kenkre, {Vaishalee P.} and Nadia Khan and Lynch, {Ryan C.} and Kami Maddocks and Jonathan McConathy and Monika Metzger and David Morgan and Carolyn Mulroney and Pullarkat, {Sheeja T.} and Rachel Rabinovitch and Rosenspire, {Karen C.} and Stuart Seropian and Randa Tao and Pallawi Torka and Winter, {Jane N.} and Joachim Yahalom and Yang, {Joanna C.} and Burns, {Jennifer L.} and Mallory Campbell and Hema Sundar",
note = "Funding Information: This activity is supported by educational grants from AstraZeneca; BeiGene; Exact Sciences; Gilead Sciences, Inc.; GlaxoSmithKline; Lantheus Medical Imaging Inc.; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Astellas. This activity is supported by an education grant from Astellas and Seagen Inc. This activity is supported by a medical education grant from Karyopharm{\textregistered} Therapeutics. This activity is supported through an Independent Medical Education grant from Merck & Co., Inc. Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2022. All rights reserved",
year = "2022",
month = apr,
doi = "10.6004/JNCCN.2022.0021",
language = "English (US)",
volume = "20",
pages = "322--334",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",
}